Anji, Population Health Partners enter strategic collaboration to address kidney disease
Click Here to Manage Email Alerts
Anji Pharmaceuticals and Population Health Partners announced a strategic collaboration to accelerate the development of two clinical assets the Anji pipeline, one of which addresses kidney disease, according to the press release.
“We’ve built Anji to be an agile asset-centric biopharma enterprise that can repeatedly unlock value of clinical programs where we see high validation and unmet need,” Brian Hubbard, PhD, co-founder and CEO of Anji, said in the release. “Teaming up with [Population Health Partners] PHP is clearly one of those ‘1+1 = 3’ moments, where the deep skillsets of each will equip Anji to deliver life-changing medicines to patients even more quickly.”
Anji is conducting a phase 3 trial to explore ANJ900 (delayed-release metformin) as an investigational agent to ensure safe use of metformin in patients with type 2 diabetes and advanced chronic kidney disease. ANJ900 previously showed glucose lowering with “only one-third the plasma concentrations observed with currently marked formulations of metformin,” according to the press release. The recent collaboration between Anji and PHP was designed to quicken the development and approval of ANJ900 for patients with CKD.
Similarly, the collaboration is focused on ANJ908 (pradigastat), a potential treatment for chronic idiopathic constipation.
“Anji has an extraordinary team – and an inspiring proven leader in Brian. Their ability to unpack the complexities of biology, chemistry, pharmacology and clinical performance so that they can recognize high potential value and perform efficient drug development programs is highly impressive,” Clive Meanwell, MD, chairperson and managing partner of PHP, said in the release. “We will put PHP’s knowledge and experience to work in order to help Anji create value and produce a positive impact on prevalent diseases.”
Read more about
Click Here to Manage Email Alerts